[go: up one dir, main page]

CY1118655T1 - Χρηση 2,4-πυριμιδινοδιαμινων για τη θεραπεια της αθηροσκληρωσης - Google Patents

Χρηση 2,4-πυριμιδινοδιαμινων για τη θεραπεια της αθηροσκληρωσης

Info

Publication number
CY1118655T1
CY1118655T1 CY20171100070T CY171100070T CY1118655T1 CY 1118655 T1 CY1118655 T1 CY 1118655T1 CY 20171100070 T CY20171100070 T CY 20171100070T CY 171100070 T CY171100070 T CY 171100070T CY 1118655 T1 CY1118655 T1 CY 1118655T1
Authority
CY
Cyprus
Prior art keywords
treatment
pyrimidinodiamines
athleticosis
prevention
compounds
Prior art date
Application number
CY20171100070T
Other languages
English (en)
Inventor
Esteban Masuda
Jochen Schmitz
Original Assignee
Rigel Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rigel Pharmaceuticals, Inc. filed Critical Rigel Pharmaceuticals, Inc.
Publication of CY1118655T1 publication Critical patent/CY1118655T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Materials For Medical Uses (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Περιγράφονται νέες μέθοδοι και συνθέσεις για την πρόληψη και τη θεραπεία των μορφών αθηροσκλήρωσης με ενώσεις 2,4-πυριμιδινοαμίνης. Επίσης αποκαλύπτεται η επίχριση προσθετικών συσκευών, όπως στεντ, με τις ενώσεις της εφεύρεσης για την πρόληψη και/ή θεραπεία της επαναστένωσης.
CY20171100070T 2008-02-22 2017-01-18 Χρηση 2,4-πυριμιδινοδιαμινων για τη θεραπεια της αθηροσκληρωσης CY1118655T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US3090308P 2008-02-22 2008-02-22
PCT/US2009/034718 WO2009105675A1 (en) 2008-02-22 2009-02-20 Use of 2,4-pyrimidinediamines for the treatment of atherosclerosis

Publications (1)

Publication Number Publication Date
CY1118655T1 true CY1118655T1 (el) 2017-07-12

Family

ID=40559977

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20171100070T CY1118655T1 (el) 2008-02-22 2017-01-18 Χρηση 2,4-πυριμιδινοδιαμινων για τη θεραπεια της αθηροσκληρωσης

Country Status (20)

Country Link
US (1) US8530466B2 (el)
EP (1) EP2252300B1 (el)
JP (1) JP5586482B2 (el)
KR (1) KR101614555B1 (el)
CN (1) CN102014917A (el)
AU (1) AU2009215430B2 (el)
BR (1) BRPI0907724B8 (el)
CA (1) CA2715962C (el)
CY (1) CY1118655T1 (el)
DK (1) DK2252300T3 (el)
ES (1) ES2610880T3 (el)
HR (1) HRP20170050T1 (el)
HU (1) HUE030307T2 (el)
LT (1) LT2252300T (el)
MX (1) MX2010009159A (el)
PL (1) PL2252300T3 (el)
PT (1) PT2252300T (el)
RU (1) RU2490015C2 (el)
SI (1) SI2252300T1 (el)
WO (1) WO2009105675A1 (el)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI458721B (zh) 2008-06-27 2014-11-01 Celgene Avilomics Res Inc 雜芳基化合物及其用途
US11351168B1 (en) 2008-06-27 2022-06-07 Celgene Car Llc 2,4-disubstituted pyrimidines useful as kinase inhibitors
US8338439B2 (en) 2008-06-27 2012-12-25 Celgene Avilomics Research, Inc. 2,4-disubstituted pyrimidines useful as kinase inhibitors
PL2516434T3 (pl) 2009-12-23 2015-11-30 Takeda Pharmaceuticals Co Skondensowane heteroaromatyczne pirolidynony jako inhibitory SYK
JP5607241B2 (ja) 2010-05-21 2014-10-15 ケミリア・エービー 新規ピリミジン誘導体
RU2013109393A (ru) 2010-08-10 2014-09-20 Сэлджин Авиаломикс Ресеарч, Инк. Безилатная соль ингибитора втк
EP2635285B1 (en) 2010-11-01 2017-05-03 Celgene Avilomics Research, Inc. Heteroaryl compounds and uses thereof
CA2815858C (en) 2010-11-01 2018-10-16 Celgene Avilomics Research, Inc. Heterocyclic compounds and uses thereof
EP2637502B1 (en) 2010-11-10 2018-01-10 Celgene CAR LLC Mutant-selective egfr inhibitors and uses thereof
EP2688883B1 (en) 2011-03-24 2016-05-18 Noviga Research AB Pyrimidine derivatives
US9056873B2 (en) 2011-06-22 2015-06-16 Takeda Pharmaceutical Company Limited Substituted 6-aza-isoindolin-1-one derivatives
HRP20190186T4 (hr) 2011-07-28 2024-12-20 Rigel Pharmaceuticals, Inc. Nove formulacije (trimetoksifenilamino)pirimidinila
CA2853498A1 (en) 2011-10-28 2013-05-02 Celgene Avilomics Research, Inc. Methods of treating a bruton's tyrosine kinase disease or disorder
RU2711077C9 (ru) 2012-03-15 2020-08-11 Селджен Кар Ллс Соли ингибитора киназы рецептора эпидермального фактора роста
BR112014022789B1 (pt) 2012-03-15 2022-04-19 Celgene Car Llc Formas sólidas de um inibidor de quinase de receptor do fator de crescimento epidérmico, composição farmacêutica e usos do mesmo
WO2014100748A1 (en) 2012-12-21 2014-06-26 Celgene Avilomics Research, Inc. Heteroaryl compounds and uses thereof
EP2953457B1 (en) 2013-02-08 2020-04-08 Celgene CAR LLC Erk inhibitors and uses thereof
US9492471B2 (en) 2013-08-27 2016-11-15 Celgene Avilomics Research, Inc. Methods of treating a disease or disorder associated with Bruton'S Tyrosine Kinase
US9415049B2 (en) 2013-12-20 2016-08-16 Celgene Avilomics Research, Inc. Heteroaryl compounds and uses thereof
JP7118642B2 (ja) * 2014-08-08 2022-08-16 アリ リサーチ ソシエタ ア レスポンサビリタ リミタータ センプリフィカタ 炎症性およびアレルギー性病変の治療に用いるための脂肪酸とパルミトイルエタノールアミドの混合物
EP3179858B1 (en) 2014-08-13 2019-05-15 Celgene Car Llc Forms and compositions of an erk inhibitor
US12194023B2 (en) 2018-11-29 2025-01-14 The Research Foundation For The State University Of New York Compositions and methods for modular control of bioorthogonal ligation

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1047776C (zh) * 1993-10-01 1999-12-29 诺瓦蒂斯有限公司 具有药理学活性的吡啶类衍生物及其制备方法
RU2153494C2 (ru) * 1993-10-12 2000-07-27 Дзе Дюпон Мерк Фармасьютикал Компани 1-n-алкил-n-арилпиримидинамины, способ лечения заболеваний, фармацевтическая композиция
EP1107957B1 (en) 1998-08-29 2006-10-18 AstraZeneca AB Pyrimidine compounds
GB9828511D0 (en) 1998-12-24 1999-02-17 Zeneca Ltd Chemical compounds
EP1406875B1 (en) * 2001-06-26 2013-07-31 Bristol-Myers Squibb Company N-heterocyclic inhibitors of tnf-alpha expression
JP4423043B2 (ja) * 2002-01-23 2010-03-03 バイエル ファーマセチカル コーポレーション Ｒｈｏ−キナーゼ阻害剤
US7288547B2 (en) 2002-03-11 2007-10-30 Schering Ag CDK-inhibitory 2-heteroaryl-pyrimidines, their production and use as pharmaceutical agents
EP1483260A1 (de) 2002-03-11 2004-12-08 Schering Aktiengesellschaft Cdk inhibitorische 2-heteroaryl-pyrimidine, deren herstellung und verwendung als arzneimittel
GB0321710D0 (en) 2003-09-16 2003-10-15 Novartis Ag Organic compounds
TW200517057A (en) * 2003-09-22 2005-06-01 Basf Ag Fungicidal mixtures
CA2579007A1 (en) * 2004-09-10 2006-03-16 Altana Pharma Ag Ciclesonide and syk inhibitor combination and methods of use thereof
EP2161275A1 (en) * 2005-01-19 2010-03-10 Rigel Pharmaceuticals, Inc. Prodrugs of 2,4-pyrimidinediamine compounds and their uses
DE102005016634A1 (de) 2005-04-12 2006-10-19 Merck Patent Gmbh Neuartige Aza-Hetercyclen als Kinase-Inhibitoren
WO2007008541A2 (en) * 2005-07-08 2007-01-18 Kalypsys, Inc. Cellular cholesterol absorption modifiers
NZ592990A (en) 2005-11-01 2013-01-25 Targegen Inc Bi-aryl meta-pyrimidine inhibitors of kinases
WO2007146977A1 (en) 2006-06-15 2007-12-21 Boehringer Ingelheim International Gmbh 2-anilino-4-aminoalkyleneaminopyrimidines
CA2656290A1 (en) 2006-07-05 2008-01-10 Exelixis, Inc. Methods of using igf1r and abl kinase modulators
WO2009012421A1 (en) 2007-07-17 2009-01-22 Rigel Pharmaceuticals, Inc. Cyclic amine substituted pyrimidinediamines as pkc inhibitors

Also Published As

Publication number Publication date
KR101614555B1 (ko) 2016-04-21
EP2252300B1 (en) 2016-10-19
ES2610880T3 (es) 2017-05-03
SI2252300T1 (sl) 2017-04-26
PT2252300T (pt) 2017-01-06
US20110046126A1 (en) 2011-02-24
RU2010138899A (ru) 2012-03-27
CN102014917A (zh) 2011-04-13
HRP20170050T1 (hr) 2017-03-10
US8530466B2 (en) 2013-09-10
BRPI0907724B8 (pt) 2021-05-25
BRPI0907724A2 (pt) 2017-06-13
BRPI0907724B1 (pt) 2019-12-17
PL2252300T3 (pl) 2017-04-28
DK2252300T3 (en) 2017-02-06
RU2490015C2 (ru) 2013-08-20
EP2252300A1 (en) 2010-11-24
AU2009215430A1 (en) 2009-08-27
AU2009215430B2 (en) 2015-02-12
WO2009105675A1 (en) 2009-08-27
HK1150555A1 (en) 2012-01-06
CA2715962C (en) 2017-03-07
LT2252300T (lt) 2017-02-10
JP2011513230A (ja) 2011-04-28
KR20100126422A (ko) 2010-12-01
HUE030307T2 (en) 2017-04-28
CA2715962A1 (en) 2009-08-27
MX2010009159A (es) 2010-09-14
JP5586482B2 (ja) 2014-09-10

Similar Documents

Publication Publication Date Title
CY1118655T1 (el) Χρηση 2,4-πυριμιδινοδιαμινων για τη θεραπεια της αθηροσκληρωσης
CY1118143T1 (el) Ετεροκυκλικες ενωσεις χρησιμες ως αναστολεις της pdk1
CY1119534T1 (el) Παραγωγα φωσφορου ως αναστολεις κινασης
CY1113485T1 (el) Ενωσεις γεφυρωμενης-πιπεριδινης τυπου υποκατεστημενης-κινοξαλινης και οι χρησεις εξ' αυτων
CY1121125T1 (el) Συνθεσεις για τη θεραπευτικη αντιμετωπιση του πονου και/ή της φλεγμονης
CY1114981T1 (el) Προφαρμακα ντολουτεγκραβιρης
CY1115952T1 (el) Παραγωγα πυραζολο πυριδινης σαν αναστολεις της οξειδασης nadρη
EA200901653A1 (ru) ОПОСРЕДУЕМОЕ PHKi ИНГИБИРОВАНИЕ ЭКСПРЕССИИ АЛЬФА-EnaC
CY1121824T1 (el) Μεθοδοι και συνθεσεις για προληψη και ανακουφιση μυικων κραμπων και για αποκατασταση απο νευρομυικη ευερεθιστικοτητα και κοπωση μετα απο ασκηση
TR200906131T1 (tr) Aktivin -actrIIa antagonistleri ve göğüs kanserinin tedavi e
CY1113963T1 (el) Φαρμακευτικες συνθεσεις οι οποιες περιλαμβανουν ανταγωνιστες ακτιβινης-actriia και χρηση αυτων στην προληψη η' θεραπευτικη αγωγη πολλαπλου μυελωματος
ATE541597T1 (de) Implantierbare vorrichtung mit sich langsam auflösendem polymer
CO6361927A2 (es) Quinazolinas para inhibicion de pdk1
EA201170832A1 (ru) Пуриновые соединения
CY1108843T1 (el) 3,11β cis διϋδροτετραβεναζινη για την θεραπεια της σχιζοφρενιας και αλλων ψυχωσεων
CY1119780T1 (el) Παραγωγα πυραζολινοδιονης σαν αναστολεις της οξειδασης nadph
MX2010010406A (es) Tetrahidrofenantridinonas y tetrahidrociclopentaquinolinonas como inhibidores de la polimerizacion de poli(adp-ribosa)polimerasa-1 y tubulina.
EA201201608A1 (ru) Солнцезащитная композиция
ATE505191T1 (de) Ectoin zur behandlung von vascular leaks
ECSP11011021A (es) Antagonistas de la via hedgehog de ftalazina disustituida
MX2021001471A (es) Benzimidazoles sustituidos como inhibidores de peptidil arginina deiminasa 4 (pad4).
ATE509931T1 (de) Azaadamantanester- und carbamatderivate sowie anwendungsverfahren dafür
CY1114045T1 (el) Φαρμακευτικη συνθεση με παρατεταμενη απελευθερωση οξικης οκτρεοτιδης
CY1119785T1 (el) 2,4,6-τριφθορο-ν-[6-(1-μεθυλο-πιπεριδινο-4-καρβονυλο)-πυριδιν-2-υλο]-βενζαμιδιο για την αντιμετωπιση ημικρανιας μεσω της στοματικης ή της ενδοφλεβιας οδου
CY1113743T1 (el) Παραγωγα ισοκινολινονης ως ανταγωνιστες toy νκ3